Abstract:Metastatic breast cancer (MBC) is the most advanced stage of breast cancer. Our understanding of the molecular mechanisms which drive MBC remain incomplete. Epithelial to mesenchymal transition (EMT) and mesenchymal to epithelial transition (MET) promote drug resistance and metastasis. It has been reported that fibroblast growth factor receptor 1 (FGFR1) plays a key role during the EMT:MET cycle. Furthermore, FGFR1 is amplified in 13% of primary and 20% of metastatic breast cancer patients. Therefore, optimizing inhibition of FGFR1 is crucial for the therapeutic targeting of the late stage breast cancer. First, we examined the efficacies of FGFR kinase inhibitors in the murine based dormant 4T07 tumor model. Inhibition of FGFR kinase activity leads to tumor growth inhibition but fail to eradicate dormant breast cancer cells. Therefore, we explored broader approaches to inhibit FGFR1 expression in addition to blockade of its kinase activity. G-quadruplex (G4) structures are secondary DNA structures commonly found upstream of transcriptional start sites (TSS) of oncogenes restricting their expression. Consequently, pharmacological stabilization of G4 structures within the promoters of cancer-related genes via use of small molecules has emerged as a promising therapeutic approach in cancer. Results herein demonstrate that the proximal promoter of FGFR1 contains sequences that form G4. Circular dichroism was used to verify formation of G4 in the FGFR1 proximal promoter. Importantly, use of the G4-binding compound CX-5461 stabilized the FGFR1 G4 structure, blocked the transcriptional activity of the FGFR1 proximal promoter and decreased FGFR1 expression. Therefore, we implemented the G4 stabilizers in FGFR1 expressing and metastatic drug-resistant BC cell lines. This approach results in dramatic downregulation of FGFR1 at the protein level after treatment with the G4 stabilizer. G4 stabilizing agents also interfere with ectopic FGFR1 expression and EMT-driven FGFR1 expression. Importantly, use of the G4-targeting compound CX5461 effectively blocked FGFR1 expression and inhibited FGFR1 downstream signaling, resulting in eradication of dormant breast cancer cells. Finally, in vivo application of CX5461 reduced FGFR1 expression, blocked pulmonary tumor formation and prolonged animal survival. In conclusion, consistent with the clinical observations our evaluation of FGFR kinase inhibitors validates the resistance to FGFR kinase inhibitors in MBC. Our findings indicate that targeting FGFR1 expression through G4 stabilization may be a potential strategy for MBC. Citation Format: Muhammad Safdar, Hang Lin, Sarah Dagher, Jonathan Dickerhoff, Mitchell Ayers, Luis Solorio, Danzhou Yang, Michael Wendt, Saeed Akhand. Targeting fibroblast growth factor receptor (FGFR1) expression through G-quadruplex stabilization inhibits metastatic breast cancer [abstract]. In: Proceedings of the 2023 San Antonio Breast Cancer Symposium; 2023 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2024;84(9 Suppl) nr PO2-18-06.

Investigation of G-Quadruplex Formation in the Fgfr2 Promoter Region and Its Transcriptional Regulation by Liensinine

Expression and Purification of FGFR1-Fc Fusion Protein and Its Effects on Human Lung Squamous Carcinoma

G-quadruplex structures in FGFR3 promoter negatively regulate its gene expression and DNA replication

Fibroblast growth receptor 1 is regulated by G-quadruplex in metastatic breast cancer

Exploration of the Structure and Recognition of a G-quadruplex in the Her2 Proto-oncogene Promoter and Its Transcriptional Regulation.

Exploring the Formation and Recognition of an Important G-Quadruplex in a HIF1α Promoter and Its Transcriptional Inhibition by a Benzo[c]phenanthridine Derivative

A Newly Identified G-quadruplex As a Potential Target Regulating Bcl-2 Expression

Existence of G-quadruplex Structures in Promoter Region of Oncogenes Confirmed by G-quadruplex DNA Cross-Linking Strategy.

Investigation on the Formation, Conversion and Bioactivity of A G-Quadruplex Structure in the Palb2 Gene

Stabilization of VEGF G-quadruplex and Inhibition of Angiogenesis by Quindoline Derivatives

FGF19 Genetic Amplification As a Potential Therapeutic Target in Lung Squamous Cell Carcinomas.

Abstract LB430: Identification of therapeutic target in breast cancer using G-quadruplex binding ligands

Study of G-Quadruplexes in the Stat3 Gene Using Electrospray Ionization Mass Spectrometry

Abstract 5775: Structure and dynamics of the major PDGFR- β oncogene promoter G-quadruplex and insights into its cellular regulation

Formation, Recognition and Bioactivities of a Novel G-quadruplex in the STAT3 Gene

11-Amino-5-n-methyl-7-fluorine- Quindoline Derivatives: the Potential Anti-angiogenic Agents Targeting G-quadruplex Structure in Vascular Endothelial Cell Growth Factor

Abstract PO2-18-06: Targeting fibroblast growth factor receptor (FGFR1) expression through G-quadruplex stabilization inhibits metastatic breast cancer

Electrospray ionization mass spectrometric exploration of the high-affinity binding of three natural alkaloids with the mRNA G-quadruplex in the BCL2 5'-untranslated region.

Spectral Analysis of Interaction Between Human Telomeric G-Quadruplex and Liliflorin A, the First Lignan Derivative Interacted with G-Quadruplex Dna

Targeting G-rich sequence to regulate the transcription of murine double minute (MDM) genes in triple-negative breast cancers

EGFR suppression contributes to growth inhibitory activity of G-quadruplex ligands in non-small cell lung cancers